Vall d’Hebron leads a European project to test a new, more effective and less toxic drug against childhood cancer

by Vall d’Hebron

The PHOENIX project, involving 13 European institutions, will evaluate for the first time in paediatric patients the drug ibrilatazar from AbilityPharma in a phase I/II clinical trial.

Read more

AbilityPharma’s IBRILATAZAR (ABTL0812) doubles overall survival in patients with squamous non-small cell lung cancer

by AbilityPharma

The trial evaluated the safety and efficacy of ibrilatazar (ABTL0812) combined with paclitaxel/carboplatin in 40 patients with stage III/IV squamous non-small cell lung cancer (sq-NSCLC), at 6 leading...

Read more

IBRILATAZAR (ABTL0812) from AbilityPharma increases chemotherapy effectiveness by 40% in patients with endometrial cancer

by AbilityPharma

The trial evaluated the safety and efficacy of ibrilatazar (ABTL0812) combined with paclitaxel/carboplatin in 51 patients with advanced or recurrent endometrial cancer, across 9 leading oncology hospi...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Rethinking Alzheimer’s clinical trials...

by Fundació Clínic per a la Recerca Biomèdica

A paper published in Alzheimer’s & Dementia: The Journal of the Alzh...

Photos Stream